About one in eight US adults is currently taking a GLP-1 drug , according to a Kaiser Family Foundation (KFF) poll from late 2025. Almost none of them pay list price.

Wegovy lists around $1,349 a month. Zepbound is $1,086 monthly. Yet, an informed buyer in 2026 pays somewhere between $25 and $450 a month. And sometimes nothing at all. Three things determine what people pay: what insurance they have, which drug and dose they are on, and which channel the prescription travels through.

What’s clear is that getting a GLP-1 at the best price is genuinely complicated. Here are ways to get the GLP-1 drugs for the cheapest price depending on your situation.

Commercial Insurance: As Little As $25

For a patient with commercial insurance and a covered indication, nothing in the cash market comes close. Lilly prices Foundayo, its new weight-loss pill, at $25 a month for commercially insured patients with a savings card. However, it is subject to a fill limit and the price expires at the end of 2026. Novo Nordisk’s Wegovy savings card covers up to $100 per month. This means you will only pay the advertised $25 price if your insurance copay is $125 or less.

But the catch on these super-low prices is whether your insurance actually covers it. In KFF’s 2025 employer survey , only 19% of firms with 200 or more workers covered GLP-1s used primarily for weight loss in their largest health plan. Where coverage exists, approval usually hinges on body mass index (BMI) thresholds, comorbidities or prior lifestyle interventions.

Medicare: A Flat $50, With Conditions

The Medicare GLP-1 Bridge launched July 1 and runs through December 31, 2027. Eligible Part D beneficiaries pay a flat $50 a month for Foundayo, Wegovy tablets and injections and the Zepbound KwikPen.

Eligibility is specific: a BMI of 35 or higher; 30 or higher with heart failure, uncontrolled hypertension or chronic kidney disease; or 27 or higher with prediabetes, prior heart attack, prior stroke or symptomatic peripheral arterial disease. These criteria are assessed at the time therapy began, including for patients who started before July.

The exclusions are important in this program. Zepbound single-dose vials and pens are not covered. Neither are Ozempic, Mounjaro or any compounded product. The program also sits outside the standard Part D benefit. Therefore, the $50 does not count toward a deductible or the annual out-of-pocket cap. Low-income subsidies also do not apply, and no coupon can be used to further reduce the price. Yet, beneficiaries who fall outside the Medicare’s GLP-1 Bridge can still get semaglutide through Part D under a diabetes or cardiovascular indication.

Separately, CMS has set an Inflation Reduction Act price of $274 for a 30-day supply of semaglutide. This includes the brands Ozempic, Rybelsus and Wegovy which are treated as one drug. This will begin January 1, 2027. It is roughly 71% below the $959 benchmark from CMS.

Importantly, it applies only to Medicare. The administration’s separate most-favored-nation deal set a $245 price that CMS has indicated is expected to supersede it.

GLP-1 Pills Are The Cheapest Cash Option

Novo’s Wegovy tablet reached the market in January. Lilly’s orforglipron , sold as Foundayo, was approved April 1.

Both start at $149, and both escalate with higher doses. Novo’s tablet runs $149 monthly for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg. The 4 mg dose was $149 until August 31 and has since stepped up. Foundayo runs $149 a month for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg, and $349 at the top two doses.

This requires a refill within 45 days to hold the lower price. Lilly has temporarily cut 2.5 mg to $149 a month and 5.5 mg to $199 through December 31.

Therefore, the lower prices are for a starting dose on both products. A patient at a maintenance dose should expect to pay $299 or more a month.

Injectables, And The Channel Rule That’s Changed

Cash prices on injectable GLP-1s have fallen hard. Novo cut Wegovy and most Ozempic doses to $349 a month, with $199 on the first two fills of the starting doses. Lilly put Zepbound at $299 a month for 2.5 mg and $399 for 5 mg. This is roughly 63% to 72% below list price.

It’s important to know that the widely quoted $449 a month maintenance figure is promotional. It applies at 7.5 mg and above and requires a refill purchase within 45 days of the previous delivery. Lilly’s regular self-pay price is $499 a month at 7.5 mg and $699 at 10 mg and above. So a missed window can cost $250 in a single month.

Where the drug gets prescribed used to matter more than it does now. Through 2025, Lilly’s discounted pricing was locked to LillyDirect. Yet since March, the Zepbound KwikPen has been available at self-pay pricing at Kroger, Publix, CVS, Walgreens, Costco, Walmart and Amazon Pharmacy through the KwikPen Self-Pay Savings Card. This is open to all patients including the uninsured.

The card covers only the KwikPen. Single-dose vials remain a LillyDirect product.

TrumpRx, the federal platform launched in February, does not sell drugs. It routes patients to the manufacturers’ own discount sites. Starting-dose injectables run near $350 a month under most-favored-nation commitments with a stated path toward $245.

GLP-1 Indication Often Matters More Than Brand

Semaglutide sold as Ozempic for type 2 diabetes carries different coverage rules than the same molecule sold as Wegovy for weight loss. Part D plans routinely cover the first while excluding the second. Formulation has also stopped mattering: the multi-dose KwikPen, approved in January and launched in February, is now priced at parity with vials on self-pay. Health savings and flexible spending dollars apply with a valid prescription.

Copay cards are closed to anyone on Medicare, Medicaid, TRICARE or VA benefits. Self-pay is murkier.

Novo’s pharmacy terms include that government beneficiaries can buy at cash prices if they purchase entirely outside their plan and never submit a claim. Other legal experts argue that the federal anti-kickback statute excludes them outright.

Anyone in that position should check the manufacturer’s current terms and ask the dispensing pharmacy.

Compounded Drugs Are Cheaper, But Their Availability Is Increasingly Precarious

Compounded semaglutide and tirzepatide still advertise at roughly $150 to $300 a month. Gallup found 19% of current GLP-1 users on a compounded or custom-mixed version. But the legal ground that supports those prices has been significantly eroded.

The FDA declared the tirzepatide shortage resolved in late 2024 and semaglutide in February 2025. This ends the basis for large-scale compounding, which can only be done when drugs are in shortage.

On April 30 the agency proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk substances list , finding no clinical need. The comment period closed July 30 and a final determination is pending. Dozens of warning letters have gone out and several major telehealth platforms have left the category.

However, patient-specific compounding at 503A pharmacies continues. This is why smaller operations can still advertise for it. But for patients considering this pathway, supply interruption is a real risk. Additionally, compounded products are not FDA-reviewed for potency, purity or dosing accuracy.

Every Legitimate Route Requires A Prescription

No FDA-approved GLP-1 is sold over the counter, and none of these programs work without one. Additionally, every GLP-1 approved for weight management carries a boxed warning for thyroid cancer. Prescribing requires screening for personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis and concurrent GLP-1 use.

For patients considering less legitimate ways to obtain GLP-1s, it is important to know that peptides or imported vials sold online without a prescription are not a cheaper version of the same medication. They are unapproved drugs of unverified content.

Finally, two free routes also exist, and both are underused. Manufacturer assistance programs supply branded GLP-1s at no cost to uninsured patients below income thresholds. However, renewal is annual and not every product is included. Obesity trials are still enrolling and provide drug and monitoring at no charge. However, it is possible that taking this route may involve being assigned to a placebo.

Getting a cheap GLP-1 drug has never been more possible, or more complicated. People should also know that promotional pricing expires, and that doses escalate during titration which can increase prices. Manufacturers also reserve the right to change programs without notice.

The only number worth acting on is the one verified on the manufacturer’s own page that week.